Shape information in repeated glucose curves during pregnancy provided significant physiological information for neonatal outcomes

PLoS One. 2014 Mar 11;9(3):e90798. doi: 10.1371/journal.pone.0090798. eCollection 2014.

Abstract

Objective: To use multilevel functional principal component analysis to exploit the information inherent in the shape of longitudinally sampled glucose curves during pregnancy, and to analyse the impact of glucose curve characteristics on neonatal birth weight, percentage fat and cord blood C-peptide.

Study design and setting: A cohort study of healthy, pregnant women (n = 884). They underwent two oral glucose tolerance tests (gestational weeks 14-16 and 30-32), which gave two glucose curves per woman.

Results: Glucose values were higher, and peaked later in third trimester than in early pregnancy. The curve characteristic "general glucose level" accounted for 91% of the variation across visits, and 72% within visits. The curve characteristics "timing of postprandial peak", and "oscillating glucose levels" accounted for a larger part of the variation within visits (15% and 8%), than across visits (7% and <2%). A late postprandial peak during pregnancy, and high general glucose levels in third trimester had significant, positive effects on birth weight (p<0.05). Generally high glucose levels during pregnancy had a significant, positive impact on neonatal percentage fat (p = 0.04). High general glucose level in third trimester had a significant, positive impact on cord blood C-peptide (p = 0.004).

Conclusion: Shape information in entire OGTT curves provides significant physiological information of importance for several outcomes, and may contribute to the understanding of the metabolic changes during pregnancy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Birth Weight*
  • Blood Glucose*
  • C-Peptide / blood
  • Female
  • Fetal Blood / metabolism
  • Humans
  • Infant, Newborn
  • Pregnancy
  • Regression Analysis
  • Risk Factors
  • Young Adult

Substances

  • Blood Glucose
  • C-Peptide

Grants and funding

Funding for the study was provided by the Norwegian Health Association; Faculty of Medicine, University of Oslo; Department of Obstetrics and Gynaecology and the National Resource Centre for Women's Health, Oslo University Hospital Rikshospitalet. Roche Diagnostics, Norway supplied glucometers and test strips free of charge. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.